Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAFV600E: New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment (Frontiers in Endocrinology, (2013), 4, (189), 10.3389/fendo.2013.00189);Thrombospondin-1 silencing down-regulates integrin expression levels in human anaplastic thyroid cancer cells with BRAFV600E: New insights in the host tissue adaptation and homeostasis of tumor microenvironment

Frontiers in Endocrinology

Volumn 4, Issue DEC, 2013, Pages

  Duquette, Mark ^a   Sadow, Peter M ^a   Lawler, Jack ^a   Nucera, Carmelo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Extracellular matrix; Integrins; Microenvironment; Thyroid cancer; TSP 1; extracellular matrix; thyroid cancer; BRAFV600E; integrins; microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHA3 INTEGRIN; ALPHA6 INTEGRIN; B RAF KINASE; BETA1 INTEGRIN; CD45 ANTIGEN; GREEN FLUORESCENT PROTEIN; INTEGRIN RECEPTOR; THROMBOSPONDIN 1;

ANAPLASTIC THYROID CANCER; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RETRIEVAL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LENTIVIRINAE; MACROPHAGE; METASTASIS POTENTIAL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 84892178310     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2020.596223     Document Type: Erratum

References (31)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 295(18):2164-7. doi: 10.1001/jama.295.18.2164.
2. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid (2004) 14(12):1056-60. doi:10.1089/thy.2004.14.1056.
3. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 22(11):1104-39. doi:10.1089/thy.2012.0302.
4. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 69(11):4885-93. doi:10.1158/0008-5472.CAN-09-0727.
5. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 107(23):10649-54. doi:10.1073/pnas.1004934107.
6. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 108(4):1615-20. doi:10.1073/pnas.1015557108.
7. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 71(7):2417-22. doi:10.1158/0008-5472.CAN-10-3844.
8. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 16(3):296-309. doi:10.1634/theoncologist.2010-0317.
9. John AS, Rothman VL, Tuszynski GP. Thrombospondin-1 (TSP-1) stimulates expression of integrin alpha6 in human breast carcinoma cells: a downstream modulator of TSP-1-induced cellular adhesion. J Oncol (2010) 2010:645376. doi:10.1155/2010/645376.
10. Chandrasekaran S, Guo NH, Rodrigues RG, Kaiser J, Roberts DD. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem (1999) 274(16):11408-16. doi:10.1074/jbc.274.16.11408.
11. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol (2004) 36(6):961-8.
12. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci (2008) 65(5):700-12. doi:10.1007/s00018-007-7486-z.
13. Hynes RO. The extracellular matrix: not just pretty fibrils. Science (2009) 326(5957):1216-9. doi:10.1126/science.1176009.
14. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat (2009) 114(1):85-96. doi:10.1007/s10549-008-9992-6.
15. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene (2004) 23(36):6031-9. doi:10.1038/sj.onc.1207812.
16. Legrand C, Thibert V, Dubernard V, Begault B, Lawler J. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. Blood (1992) 79(8):1995-2003.
17. Saumet A, Slimane MB, Lanotte M, Lawler J, Dubernard V. Type 3 repeat/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47/alphavbeta3 in promyelocytic leukemia NB4 cells. Blood (2005) 106(2):658-67. doi:10.1182/blood-2004-09-3585.
18. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest (1998) 101(5):982-92. doi:10.1172/JCI1684.
19. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 19(10):1077-84. doi:10.1089/thy.2009.0055.
20. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, et al. SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 209(7):1289-307. doi:10.1084/jem.20112446.
21. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One (2013) 8(1):e54302. doi:10.1371/journal.pone.0054302.
22. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 15(4):1069-74. doi:10.1677/ERC-08-0036.
23. Trevino-Villarreal JH, Cotanche DA, Sepulveda R, Bortoni ME, Manneberg O, Udagawa T, et al. Host-derived pericytes and Sca-1+ cells predominate in the MART-1-stroma fraction of experimentally induced melanoma. J Histochem Cytochem (2011) 59(12):1060-75. doi:10.1369/0022155411428078.
24. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, Bidart JM, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One (2011) 6(7):e22567. doi:10.1371/journal.pone.0022567.
25. Hayden K, Tetlow L, Byrne G, Bundred N. Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann Clin Biochem (2000) 37(Pt 3):319-25. doi:10.1258/0004563001899212.
26. Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, et al. Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol (2007) 31(5):1127-32.
27. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 108(24):9939-44. doi:10.1073/pnas.1105041108.
28. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res (2004) 64(5):1570-4. doi:10.1158/0008-5472.CAN-03-3126.
29. Firlej V, Mathieu JR, Gilbert C, Lemonnier L, Nakhle J, Gallou-Kabani C, et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors. Cancer Res (2011) 71(24):7649-58. doi:10.1158/0008-5472.CAN-11-0833.
30. Kim SK, Kim DK, Oh IH, Song JY, Kwon KH, Choe BK, et al. A missense polymorphism (rs11895564, Ala380Thr) of integrin alpha 6 is associated with the development and progression of papillary thyroid carcinoma in Korean population. J Korean Surg Soc (2011) 81(5):308-15. doi:10.4174/jkss.2011.81.5.308.
31. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A (2009) 106(25):10290-5. doi:10.1073/pnas.0904227106.